Advanced

Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel

Poikonen, P; Sjostrom, J; Klaar, S; Nittby, LT; Sigurdsson, H; Madsen, EL; Joensuu, H and Blomqvist, C (2004) In Acta Oncologica 43(2). p.190-195
Abstract
Docetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m(2)) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37 - 6.47), oral mucositis (1.98, CI 1.30 - 3.04), and the leukocyte nadir (0.12, CI 0.02 - 0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection ( 2.75, CI 1.00 -... (More)
Docetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m(2)) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37 - 6.47), oral mucositis (1.98, CI 1.30 - 3.04), and the leukocyte nadir (0.12, CI 0.02 - 0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection ( 2.75, CI 1.00 - 7.58). A major infection was diagnosed in 62% ( 8 out of 13) of the docetaxel cycles in severely ( grade 4) leukopenic patients who had grade 2 to 4 skin toxicity. Major infections are common in leukopenic patients who develop docetaxel-associated skin toxicity, and leukopenic patients presenting with docetaxel-induced skin toxicity may be candidates for prophylactic anti-infection measures such as prophylactic therapy with hematopoietic growth factors. (Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
43
issue
2
pages
190 - 195
publisher
Taylor & Francis
external identifiers
  • wos:000220516200010
  • pmid:15163169
  • scopus:11144353697
ISSN
1651-226X
DOI
10.1080/02841860310022977
language
English
LU publication?
no
id
ce518d05-4a10-464e-a9ed-ea3a09bf0020 (old id 899186)
date added to LUP
2008-01-18 11:13:49
date last changed
2017-04-30 14:23:12
@article{ce518d05-4a10-464e-a9ed-ea3a09bf0020,
  abstract     = {Docetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m(2)) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37 - 6.47), oral mucositis (1.98, CI 1.30 - 3.04), and the leukocyte nadir (0.12, CI 0.02 - 0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection ( 2.75, CI 1.00 - 7.58). A major infection was diagnosed in 62% ( 8 out of 13) of the docetaxel cycles in severely ( grade 4) leukopenic patients who had grade 2 to 4 skin toxicity. Major infections are common in leukopenic patients who develop docetaxel-associated skin toxicity, and leukopenic patients presenting with docetaxel-induced skin toxicity may be candidates for prophylactic anti-infection measures such as prophylactic therapy with hematopoietic growth factors.},
  author       = {Poikonen, P and Sjostrom, J and Klaar, S and Nittby, LT and Sigurdsson, H and Madsen, EL and Joensuu, H and Blomqvist, C},
  issn         = {1651-226X},
  language     = {eng},
  number       = {2},
  pages        = {190--195},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel},
  url          = {http://dx.doi.org/10.1080/02841860310022977},
  volume       = {43},
  year         = {2004},
}